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Abstract
Background: Pulmonary arterial hypertension is of importance in congenital cardiac surgery
as being a significant cause of morbidity and mortality. Although therapy options are limited,
inhaled nitric oxide (NO) is used as a standard therapy. The present study aimed to compare
inhaled NO and aerosolized iloprost in children with secondary pulmonary hypertension who
underwent congenital cardiac surgery.
Methods: Sixteen children included in the study were randomized into either inhaled NO or
aerosolized iloprost group. For both groups, the observation period terminated at 72 h after
cardiopulmonary bypass.
Results: There was no significant difference between the groups in terms of mean age, weight,
cross clamp time, pump time, and extubation time. No significant change was observed in the
arterial tension and central venous pressure of both groups before the operation, 30 min after
the pump, 45 min after the pump, and after extubation, whereas an increase was observed in
the heart rate and cardiac output, and a decrease was observed in the pulmonary artery
pressure. The mean values at the above-mentioned time points showed no difference between
the groups. No serious adverse event and mortality was detected.
Conclusions: Both inhaled NO and aerosolized iloprost were found to be effective and
comparable in the management of pulmonary hypertension. (Cardiol J 2012; 19, 4: 387–394)
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Introduction
Pulmonary hypertension, a life-threatening di-
sease, is characterized by vasoconstriction and pro-
gressive remodeling of the pulmonary arterial wall
causing right ventricular failure and death. Conge-
nital heart disease is responsible for pulmonary hy-
pertension in children in approximately 50% of cas-
es [1]. Generally, correction of cardiac malforma-
tion could not be carried out in patients with con-
genital heart disease and severe pulmonary arteri-
al hypertension. Recently, understanding the
pulmonary arterial hypertension pathogenesis has
led to the development of therapeutic approaches
for pulmonary arterial hypertension including the
uses of endothelin receptor antagonists [2], pros-
tacyclin analogs [3], and phosphodiesterase-5 inhibi-
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tors [4]. Nitric oxide (NO) is biologically identical
to endothelium-derived relaxing factor, which has
been shown to mediate vascular dilatation. When
released, NO diffuses into the vascular smooth mus-
cle cells and activates the soluble guanylate cycla-
se. Activation of soluble guanylate cyclase increas-
es the concentration of cyclic guanosine monophos-
phate and initiates a cascade of events resulting in
smooth muscle relaxation. Several evidences indi-
cate that NO is an important mediator of pulmonary
vascular tone [5]. Therefore, inhaled NO, as a se-
lective pulmonary vasodilator, has been the treat-
ment of choice for controlling pulmonary hyperten-
sion after cardiac surgery. The use of inhaled NO
leads to an improvement in pulmonary hyperten-
sion and a decrease in the ratio of pulmonary artery
pressure to systemic artery pressure [5, 6].
Various methods have been tried to enhance
the effect of NO in children with congenital heart
disease. The effect of NO can be enhanced by pre-
cise patient selection, supplemental agents, and
gradual withdrawal [6].
Prostacyclin induces a stimulation of adenylat-
cyclase by binding to specific membrane receptors
(IP-receptors) and other receptors that are localized
on the cell surface or in the nucleus. The result is
an increase of the cyclic 3’, 5’-adenosin monophos-
phate (cAMP) level. Increase of the ‘second mes-
senger’ cAMP in the muscle cells activates the cal-
cium pumps and thus makes the calcium stream out
of the cytoplasm, increased intracellular cAMP level
inhibits the myosin kinases. This results in vasore-
laxation with a reduction of vessel resistance and
an increased blood flow. Iloprost has a similar phar-
macological profile to endogenous PGI2. This
has been shown through tests with several animal
species, in healthy human test subjects and also in
patients [7]. The elimination half-life of inhaled ilo-
prost is 20–30 min; it is selective for pulmonary
vasculature and used as a specific vasodilator [8].
The aim of the present study was to compare
the acute hemodynamic effects of aerosolized ilo-
prost and inhaled NO in secondary pulmonary hy-
pertension in children undergoing congenital heart
surgery.
Methods
Sixteen children with severe pulmonary arte-
rial hypertension (pulmonary arterial/aortic pres-
sure ratio, greater than 0.7) who underwent cardiac
surgery at our institution for congenital cardiac
defects between September 2009 and November
2011 were enrolled in the present study. Only pa-
tients who fulfilled the diagnostic criteria of the
National Institutes of Health Registry for primary
pulmonary hypertension were included [1]. The
study was approved by the Ethical Committee of our
hospital. Informed consent was obtained from the
relatives of the patients. Patients older than
24 months and/or echocardiographic and clinical fin-
dings suggestive of fixed pulmonary hypertension
(forexample; right heart enlargement, normal or de-
creased pulmonary artery flow velocity on echocar-
diogram, quite precorium with no clinical signs of
significant left to right shunting) underwent cardiac
catheterization and assessment of pulmonary vascu-
lar reactivity testing using inhaled 100% oxygen.
Surgical and anesthetic procedure
In the present study, surgical management was
standardized. We carried out intracardiac repair
through a median sternotomy with standard car-
diopulmonary bypass using bicaval cannulation,
moderate hypothermia (at 24–26oC), and antegrade
extracellular cardioplegia. All patients were nor-
moventilated by pressure-controlled ventilation
during weaning from extracorporeal circulation with
a Servo Ventilator 300/NO-A (Servo 300; Siemens,
Munich, Germany); they were then transferred to
the intensive care unit on this ventilator. For all
patients, end-tidal CO2 was kept at 35–40 mm Hg.
Patients were ventilated with 100% oxygen for
30 min and FIO2 was then decreased accordingly
monitoring individual arterial pO2 values. Positive
end-expiratory pressure was kept at 5 cmH2O.
Patients were randomized to receive either
aerosolized iloprost (iloprost group) or inhaled NO
(NO group) by an independent monitor using a com-
puter-based scheme. Iloprost and NO were admi-
nistered immediately after cardiopulmonary bypass
and before heparin reversal. Iloprost (Ilomedin,
Schering AG, Schlieren, Switzerland) was admi-
nistered at a dose of 0.5 µg/kg every 90 min for a mi-
nimum of 72 h using an ultrasound nebulizer
(MaQuet, Germany). The nebulizer was connected
to the distal inspiratory part of the respiratory cir-
cuit. Nitric oxide (Westfalen-Gas, Germany) was
administered at a dose of 20 parts per million (ppm)
using a commercially available system for NO ap-
plication and concentration measurement (Draeger
NODOMO®, Dräger, Lübeck, Germany).
The observation period was terminated at
72 h after cardiopulmonary bypass for both groups.
In the NO group, inhaled NO was also administered
for at least 72 h after cardiopulmonary bypass if
weaning was not possible. Nitric oxide or iloprost
treatment was then continued on an individual ba-
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sis, if clinically required. The endpoints were as fol-
lows: 1) cumulated mean pulmonary arterial pres-
sure and pulmonary artery pressure to systemic
artery pressure as measured with arterial lines
during the observation period, 2) duration of me-
chanical ventilation (in hours) until weaning from
the respirator.
Hemodynamic monitoring
Hemodynamic monitoring was performed in
the intensive care unit. A 5 F to 8 F introducer
sheath was placed into the right or left internal jug-
ular vein according to the age and weight of the
patients. Chest X-ray or fluoroscopy was used to
verify the correct positioning of the catheter. A 24 G
catheter was inserted into the radial artery, or
a 2 F catheter was inserted into a femoral artery
for systemic arterial pressure monitoring. Either
a Swan-Ganz catheter through the superior vena
cava or a 3 F catheter directly inserted surgically
to the main pulmonary artery was used for direct
pulmonary artery pressure monitoring. Transduc-
ers were positioned at the midaxillary line and ze-
roed at atmospheric pressure. Pulmonary arterial
pressure, systemic arterial pressure, and right atrial
pressures were continuously monitored. Cardiac
output was measured using Fick principle. Heart
rate and transcutaneous arterial oxygen saturation
were also continuously monitored. Arterial and
mixed-venous blood samples were obtained simu-
ltaneously to determine the partial pressure of ox-
ygen, partial pressure of carbon dioxide, pH, base
excess, and oxygen saturation (ABL 520, Radio-
meter, Copenhagen).
Statistical analysis
Statistical calculations were performed using
the Number Cruncher Statistical System 2007 Sta-
tistical Software program for Windows (NCSS Sta-
tistical Systems, Kaysville, Utah, USA). Standard
descriptive statistics were performed and ex-
pressed as mean and standard deviation. Groups
were compared using the Mann-Whitney U test. In
each treatment group repeated measures of Fried-
man test was used to determine the differences in
measurement at each time point. When p less than
0.05, Dunn’s multiple comparisons tests were used
for pairwise comparisons. A p value less than 0.05
was considered statistically significant.
Results
There was no significant difference between
NO and iloprost groups in terms of mean age,
weight, cross clamp time, pump time, and extuba-
tion time (Table 1).
Nitric oxide and iloprost groups were compared
in terms of arterial tension, central venous pres-
sure, heart rate, pulmonary arterial pressure, ratio
of pulmonary artery pressure to systemic artery
pressure, and cardiac output values before the op-
eration (preoperative), 30 min after the pump,
45 min after the pump, and after extubation. No differ-
ence was found between the groups in terms of the
mean values of these parameters at the above-men-
tioned time points (Table 2). Although there was
a trend towards reduction of the pulmonary artery
pressure in the NO group 45 min after the pump it
did not reach to statistical significance (p = 0.064).
Moreover, when the changes in the mean values of
these parameters were evaluated, no significant
changes were found in arterial tension and central
venous pressure values at all time points in both
groups (Fig. 1). A statistically significant change was
observed in the heart rate, cardiac output, pulmo-
nary arterial pressure, and ratio of pulmonary ar-
tery pressure to systemic artery pressure values
in both groups at all time points. As compared to
the preoperative values, an increase was observed
in heart rate and cardiac output values in both NO
and iloprost groups, whereas a decrease was ob-
served in pulmonary arterial pressure and ratio of
pulmonary artery pressure to systemic artery pres-
sure values (Figs. 2, 3).
Paired comparisons revealed that heart rate
values at the time points of 45 min after the pump
and after extubation were significantly higher as
compared to the preoperative heart rate value in the
NO group. In the iloprost group, heart rate value at
the time point of after extubation was significantly
higher than the preoperative heart rate value and
heart rate value at the time point of 45 min after
the pump. In the NO group, cardiac output values
at the time points of 30 min after the pump, 45 min
after the pump, and after extubation were signifi-
cantly higher than the preoperative cardiac output
value. In the iloprost group, cardiac output values
at the time points of 45 min after the pump and af-
ter extubation were significantly higher than the
preoperative cardiac output value there were no
severe complications associated with catheter test-
ing or drug administration. Both treatments (inha-
lation of NO and iloprost) were generally well to-
lerated. During inhalation of NO or iloprost, no side
effect was observed in any patient. Moreover, there
was no evidence of rebound pulmonary hyperten-
sion following administration of NO or iloprost. No
serious adverse events were observed during the
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observation period (72 h after cardiopulmonary by-
pass). Patient 2 in the iloprost group had thrombo-
cytopenia (less than 70 000 platelets/µL) at day 4
after cardiopulmonary bypass, which did not need
to be treated because spontaneously improved. No
mortality was noted during the observation period.
After the observation period, one in-hospital death
was observed in the NO group; the patient died
14 days after surgery due to chronic respiratory
failure.
Discussion
In children, pulmonary hypertension associat-
ed with congenital heart diseases is a major cause
of postoperative morbidity and mortality. Thus,
management of pulmonary hypertension after car-
diac surgery is of great importance [9]. On the oth-
er hand, therapy options are limited in children.
Introduction of pulmonary-specific vasodilators into
medical practice has led to a significant increase in
the quality of life and life expectancy in these pa-
tients; however, controversy still exists about the
management of pulmonary arterial hypertension.
Many reports have suggested the use of inhaled NO
to treat pulmonary hypertension after cardiac re-
pair in congenital heart disease. Miller et al. [10]
reported the effect of inhaled NO at a concentra-
tion of 10 ppm, and propagated the use of prophy-
lactic NO because NO reduced the risk of pulmo-
nary hypertensive crisis after intracardiac repair. In
their study, Day et al. [11] used inhaled NO at
a concentration of 20 ppm in 20 patients; however,
they failed to demonstrate its beneficial effects on
Table 2. Mean values of the parameters before the operation, after the pump and after extubation in
the nitric oxide and iloprost groups.
Nitric oxide group Iloprost group P
Arterial tension
Preoperative 54.13 ± 9.27 62.25 ± 17.58 0.318
30 min after the pump 60.63 ± 9.09 53.25 ± 8.17 0.092
45 min after the pump 59.50 ± 4.78 61.38 ± 12.04 0.598
After extubation 69.00 ± 17.24 73.75 ± 9.50 0.878
Central venous pressure
Preoperative 9.25 ± 2.25 11.00 ± 1.51 0.079
30 min after the pump 11.00 ± 3.30 11.25 ± 2.92 0.205
45 min after the pump 9.75 ± 3.01 9.25 ± 3.37 0.789
After extubation 8.38 ± 2.83 8.75 ± 3.45 0.874
Heart rate
Preoperative 111.75 ± 14.96 110.88 ± 14.96 0.999
30 min after the pump 123.63 ± 29.73 124.50 ± 21.21 0.563
45 min after the pump 122.75 ± 15.15 119.63 ± 12.14 0.563
After extubation 132.00 ± 19.82 139.13 ± 15.91 0.563
Cardiac output
Preoperative 2.50 ± 0.34 2.86 ± 0.60 0.248
30 min after the pump 3.21 ± 0.60 3.17 ± 0.54 0.172
45 min after the pump 3.54 ± 0.82 3.39 ± 0.54 0.227
After extubation 3.48 ± 0.64 3.31 ± 0.72 0.528
Pulmonary arterial pressure
Preoperative 45.75 ± 14.66 47.00 ± 9.52 0.713
30 min after the pump 42.25 ± 11.37 37.38 ± 4.10 0.494
45 min after the pump 31.13 ± 5.03 34.75 ± 4.95 0.064
After extubation 32.50 ± 6.19 36.75 ± 6.27 0.222
Ratio of pulmonary artery pressure to systemic artery pressure
Preoperative 0.82 ± 0.16 0.82 ± 0.14 0.832
30 min after the pump 0.70 ± 0.19 0.71 ± 0.10 0.599
45 min after the pump 0.52 ± 0.06 0.57 ± 0.05 0.084
After extubation 0.49 ± 0.13 0.47 ± 0.05 0.636
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Figure 1. Changes in arterial tension and central venous pressure values in the inhaled nitric oxide (NO) and
aerosolized iloprost groups; Preop — preoperative value; AP30 — 30 min after discontinuation of cardiopulmonary
bypass; AP45 — 45 min after discontinuation of cardiopulmonary bypass; AEx — after extubation; ILO — ilomedin;
TA — tension arterial; CVP — central venous pressure.
Figure 3. Changes in pulmonary artery pressure and pulmonary artery pressure to systemic artery pressure values in
the inhaled nitric oxide (NO) and aerosolized iloprost groups; (Preop — preoperative value; AP30 — 30 min after
discontinuation of cardiopulmonary bypass; AP45 — 45 min after discontinuation of cardiopulmonary bypass; AEx —
after extubation; ILO — ilomedin; PAP — pulmonary artery pressure; SAP — systemic arterial pressure.
Figure 2. Changes in heart rate and cardiac output values in the inhaled nitric oxide (NO) and aerosolized iloprost
groups; Preop — preoperative value; AP30 — 30 min after discontinuation of cardiopulmonary bypass; AP45 —
45 min after discontinuation of cardiopulmonary bypass; AEx — after extubation; ILO — ilomedin; HR — heart rate;
CO — cardiac output.
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pulmonary hemodynamics after correction for con-
genital heart disease. However, limitations associ-
ated with inhaled NO include inadequate prevention
of pulmonary hypertensive crisis, possible fatal re-
bound pulmonary hypertension after discontinuation
of NO, and requirement of a more complex delivery
system to administer the agent [12, 13].
Clinical studies comparing standard NO thera-
py with other pharmacological agents or evaluating
different agents are being conducted [14–16]. There
are limited studies regarding the use of inhaled ilo-
prost therapy especially in children with pulmonary
hypertension. Limsuwan et al. [8] reported inhaled
iloprost to be an effective drug for postoperative
pulmonary hypertensive crisis in children undergo-
ing congenital cardiac surgery. Aerosolized iloprost
was given by using an oxygen jet nebulizer (Del-
phenius™, Italy) connected to the endotracheal
tube. Depending on the therapeutic efficacy the
administered iloprost dosage was stepwise in-
creased. The initial dosage was 250 ng/kg over
10 min. If no significant response was observed, the
dose was firstly increased to 1000 ng/kg nebulized
over 10 min and subsequently to the maximal dos-
age of 2000 ng/kg over 10 min every 30 min up to
5 times [8]. Loukanov et al. [15] recently compared
inhaled NO with aerolized iloprost for treatment of
pulmonary hypertension in children after cardiopul-
monary bypass surgery. They used inhaled iloprost
at 0.5 µg/kg every 2 h for a minimum of 72 h using
an ultrasound nebulizer. The inhaled iloprost dose
of 0.5 µg/kg was used in our study as well in order to
achieve reported theoretical alveolar deposition of
250 ng/kg since it is known from previous studies
that administration effectiveness is about 50%. In-
haled iloprost selectively induces a decrease in pul-
monary vascular pressure with minor effects on the
systemic circulation, which is an advantage in acute
pulmonary hypertensive crisis. Inhaled iloprost de-
creases the ventilation-perfusion mismatch due to
delivery only to ventilated lung segments. This ef-
fect may cause an increase in oxygen saturation in
patients with hypoxia [17].
Responses to NO and iloprost are highly selec-
tive, and mediator pathways of these vasodilators
are different and independent. Although different
messenger pathways are activated, the final path-
way leads to smooth muscle cell relaxation [18].
Loukanov et al. [15] reported no difference between
the groups regarding the frequency of pulmonary
hypertensive crisis, mean pulmonary arterial pres-
sure and duration of mechanical ventilation. We also
found no significant difference between the effects
of NO and iloprost on hemodynamic parameters in
children with secondary pulmonary hypertension
who underwent congenital cardiac surgery. No se-
rious side effects and no mortality during the treat-
ment were observed. Neither NO nor iloprost
caused a significant change in the arterial tension
and central venous pressure values, whereas they
caused an increase in the heart rate and cardiac
output values and a decrease in the pulmonary ar-
terial pressure and ratio of pulmonary artery pres-
sure to systemic artery pressure values. Contrary
to some previous reports [19, 20], no changes were
observed in systemic artery pressure values dur-
ing iloprost inhalation in the present study. This
may be attributed to the different characteristics of
the aerosol sprays and different intrapulmonary
deposition characteristics between intubated and
non-intubated patients.
Conclusions
Children with pulmonary hypertension and
congenital heart disease, both inhaled NO and aero-
solized iloprost are effective to selectively reduce
pulmonary arterial pressure. Nebulization of ilo-
prost may be advantageous over inhalation of NO
due to the fact that it is not associated with toxic
reactions and iloprost is easily administered by
nebulizer as compared with complex delivery sys-
tem required for NO. The patients were adminis-
tered either inhaled NO or aerosolized iloprost; the
results were found to be comparable. In conclusion,
neither NO nor iloprost caused a significant change
in the arterial tension and central venous pressure
values, whereas they caused an increase in the
heart rate and cardiac output values and a decrease
in the pulmonary arterial pressure and ratio of pul-
monary artery pressure to systemic artery pressure
values; no difference was found between the groups
in terms of these effects.
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